中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
29期
23-24
,共2页
培美曲塞%多西紫杉醇%非小细胞肺癌%二线化疗
培美麯塞%多西紫杉醇%非小細胞肺癌%二線化療
배미곡새%다서자삼순%비소세포폐암%이선화료
Pemetrexed%Docetaxel%Non small cell lung cancer%Chemotherapy
目的：探讨培美曲塞二钠（pemetrexed disodium，PMD）对比多西他赛（DOC）单药二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效和毒副反应。方法选择经病理学或细胞学确诊一线治疗失败的NSCLC患者69例，分为2组，PMD组24例患者采用单药PMD治疗， DOC组采用单药DOC治疗，化疗2个周期后评价疗效及观察毒副反应。结果2组的有效率、疾病控制率、中位生存期、1年生存率比较无统计学意义（P＞0.05）；PMD组的血液学毒性（粒细胞减少）明显低于DOC组（P＞0.05），其他消化道反应、乏力、脱发等无差异（P＞0.05）。结论 PMD对比DOC单药二线治疗晚期NSCLC临床疗效相似，PMD的血液学毒性反应相对明显降低，故更适于治疗二线晚期NSCLC患者。
目的：探討培美麯塞二鈉（pemetrexed disodium，PMD）對比多西他賽（DOC）單藥二線治療晚期非小細胞肺癌(NSCLC)的臨床療效和毒副反應。方法選擇經病理學或細胞學確診一線治療失敗的NSCLC患者69例，分為2組，PMD組24例患者採用單藥PMD治療， DOC組採用單藥DOC治療，化療2箇週期後評價療效及觀察毒副反應。結果2組的有效率、疾病控製率、中位生存期、1年生存率比較無統計學意義（P＞0.05）；PMD組的血液學毒性（粒細胞減少）明顯低于DOC組（P＞0.05），其他消化道反應、乏力、脫髮等無差異（P＞0.05）。結論 PMD對比DOC單藥二線治療晚期NSCLC臨床療效相似，PMD的血液學毒性反應相對明顯降低，故更適于治療二線晚期NSCLC患者。
목적：탐토배미곡새이납（pemetrexed disodium，PMD）대비다서타새（DOC）단약이선치료만기비소세포폐암(NSCLC)적림상료효화독부반응。방법선택경병이학혹세포학학진일선치료실패적NSCLC환자69례，분위2조，PMD조24례환자채용단약PMD치료， DOC조채용단약DOC치료，화료2개주기후평개료효급관찰독부반응。결과2조적유효솔、질병공제솔、중위생존기、1년생존솔비교무통계학의의（P＞0.05）；PMD조적혈액학독성（립세포감소）명현저우DOC조（P＞0.05），기타소화도반응、핍력、탈발등무차이（P＞0.05）。결론 PMD대비DOC단약이선치료만기NSCLC림상료효상사，PMD적혈액학독성반응상대명현강저，고경괄우치료이선만기NSCLC환자。
Objective To investigate the effect of pemetrexed two sodium (pemetrexed disodium, PMD) compared with docetaxel (DOC) alone in the second-line treatment of advanced non small cell lung cancer (NSCLC) the efficacy and side effect. Methods Pathology or cytology failed first-line treatment of 69 cases of NSCLC patients, divided into 2 groups, 24 cases in PMD group using a single drug treatment of PMD, and group DOC with single drug DOC treatment, to observe the therapeutic effect and toxicity evaluation after 2 cycles of chemotherapy. Results The efifciency of the 2 groups, disease control rate, median survival time, 1 years survival rate showed no statistical signiifcance (P>0.05);PMD group of hematological toxicities (neutropenia) was signiifcantly lower than that in DOC group (P>0.05), there was no difference in other gastrointestinal reaction, fatigue, alopecia (P>0.05). Conclusion The curative effect of PMD compared with DOC alone in the second-line treatment of advanced NSCLC, PMD hematological toxicity relative reduced obviously. It is more suitable for second-line therapy for advanced NSCLC patients.
